Mometasone

證據等級: L5

預測適應症: 1 個

Mometasone: From Inflammatory Skin Conditions to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Mometasone is a potent topical corticosteroid originally used for inflammatory skin conditions such as eczema and dermatitis. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma (CTCL), with 0 clinical trials and 2 publications (both case reports) currently supporting this direction — one of which recorded mometasone as a failed prior treatment.

Quick Overview

Item	Content
Original Indication	Inflammatory skin conditions (topical corticosteroid; no formal indication text available from regulatory records)
Predicted New Indication	Primary Cutaneous T-Cell Lymphoma (CTCL)
TxGNN Prediction Score	99.36%
Evidence Level	L4
Taiwan Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the structured data source. Based on known pharmacological information, mometasone is a potent topical glucocorticoid. It exerts its effects by activating the glucocorticoid receptor (GR), which in turn suppresses the NF-κB signaling pathway — resulting in pro-apoptotic and anti-proliferative effects on T lymphocytes. This cellular-level activity forms the mechanistic basis for the TxGNN prediction.

Primary cutaneous T-cell lymphoma, particularly Mycosis Fungoides (MF), is defined by clonal malignant T-cell proliferation within the skin. Since the primary disease target (the T lymphocyte) is the same cell type suppressed by corticosteroids, there is a plausible mechanistic bridge. NCCN guidelines for early-stage MF already list topical corticosteroids as a recognized class-effect treatment option, lending indirect clinical relevance to this prediction.

However, it is important to note that no clinical trials specifically evaluating mometasone for CTCL have been registered. The available published literature does not provide controlled efficacy evidence; one case report explicitly documented mometasone as a prior treatment that failed before the patient's condition responded to an alternative agent (tapinarof). The mechanistic link is present, but drug-specific evidence is absent.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40821495	2025	Case Report	Proceedings (Baylor University. Medical Center)	62-year-old woman with cutaneous pseudolymphoma (atypical T-cell infiltrate); mometasone and tacrolimus both failed, patient subsequently responded to tapinarof — mometasone appears as a prior failed treatment, not a successful one
25442255	2015	Case Report	Journal of Cutaneous Pathology	11-year-old boy with CD8+CD56+ mycosis fungoides of cytotoxic immunophenotype; slow-progressive disease over 7 years affecting trunk and extremities — documents the clinical presentation of paediatric MF, no direct mometasone efficacy data

Taiwan Market Information

Mometasone currently has no approved products on the Taiwan market (TFDA records). No authorization table can be generated.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for mometasone specifically in primary CTCL is limited to L4 (mechanistic/indirect), with zero registered clinical trials and only two case reports — one of which records mometasone as a treatment failure. The TxGNN model score is high (99.36%), indicating strong graph-level signal, but this reflects class-effect plausibility rather than drug-specific validation.

To proceed, the following is needed:

Mechanism of action data (MOA): Retrieve full pharmacodynamic profile from DrugBank API to confirm GR-mediated pro-apoptotic activity in T cells
Safety data: Download and parse the TFDA package insert PDF to assess contraindications and key warnings before any S1 safety evaluation can proceed
Class-effect benchmarking: Identify clinical trial data for other potent topical corticosteroids (e.g., clobetasol) in early-stage MF to establish a class-level evidence anchor
Drug-specific literature search: Broaden PubMed query (e.g., "mometasone AND mycosis fungoides") to determine whether any non-trial observational data exists
Route compatibility assessment: Confirm whether topical mometasone formulations (cream/ointment) are appropriate for the target CTCL lesion distribution and stage
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.